One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents

por Coney, Joseph M, McCoy, Jasmyne E, Buxy Sinha, Samriddhi, Sonbolian, Nina, Zhou, Lujia, Hull, Thomas P, Lewis, Shawn A, Miller, David G, Novak, Michael A, Pendergast, Scott D, Pham, Hang, Platt, Sean M, Rao, Llewelyn J, Schartman, Jerome P, Singerman, Lawrence J, Donkor, Richard, Fink, Margaret, Zubricky, Ryan, Karcher, Helene
Publicado 2023

Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration

por Coney, Joseph M., Zubricky, Ryan, Sinha, Samriddhi Buxy, Sonbolian, Nina, Zhou, Lujia, Hull, Thomas P., Lewis, Shawn A., Miller, David G., Novak, Michael A., Pendergast, Scott D., Pham, Hang, Platt, Sean M., Rao, Llewelyn J., Schartman, Jerome P., Singerman, Lawrence J., Donkor, Richard, Fink, Margaret, McCoy, Jasmyne, Karcher, Helene
Publicado 2023